Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to various forms and formulations of compounds, for example, compounds that have use in pharmaceutical applications.
• API's Active pharmaceutical ingredients
• API's may be prepared in a variety of different forms, such as for example salts, solvates, hydrates, co-crystals.
• API's may also be in their amorphous state or one or several crystalline forms (polymorphs).
• polymorphs crystalline forms
• the physicochemical properties of an API may change, leading to e.g. different solubility, thermodynamic stability, density or melting point of different forms. Such physicochemical properties therefore may have significant influence of the efficacy or bioavailability of a known API.
• the present invention provides solid forms of the compound of formula 1 selected from the group consisting of: a) a substantially amorphous form of compound 1 , selected from form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI or combinations thereof, wherein compound 1 is molecularly dispersed;
• said solid form is selected from a solvate of form III, IV, V, VI, VII, IX, X, XI, XII, XIII, XIV or XV.
• said solid form is selected from a polymorph of form VIII or XVI.
• said solid form is selected from the sulfuric acid-, hydrobromic acid- or hydrochloric acid salt of compound 1.
• said solid form is a substantially amorphous form of compound 1, selected from form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV or XXVI or combinations thereof, wherein compound I is molecularly dispersed.
• the invention provides a method for treating a disease or condition in a mammal in need thereof.
• the method includes administering to the mammal an effective amount of a composition comprising a solid form compound as described herein.
• the diseases or conditions are mediated by b-Raf mutants having V600E, V600M, V600R, V600K or V600G mutations.
• the diseases or conditions include, but are not limited to melanoma, thyroid cancer and colorectal cancer.
• solid forms disclosed herein may be further processed into any type of solid pharmaceutical preparations or dosage forms, which are known to the person of skill in the art. Particularly preferred are oral dosage forms such as tablets, capsules, pills, powders, suspensions, pasts and the like. Detailed descriptions of suitable excipients as well as methods for making such pharmaceutical preparations can for example be found in: Raymond C. Rowe et al, Handbook of Pharmaceutical Excipients, 6 th edition, 2009, Pharmaceutical Press (Publ); ISBN-10: 0853697922. [0012] Consequently, so obtained pharmaceutical preparations form further embodiments provided herein.
• Figure 1 shows XRPD patterns of the amorphous form of compound 1 as obtainable by the method disclosed in Example 1.
• Figure 2 shows the XRPD patterns of form III of compound 1 as obtained by the method disclosed in Example 3.
• Figure 3 shows the XRPD patterns of form IV of compound 1 as obtained by the method disclosed in Example 4.
• Figure 4 shows the XRPD patterns of form V of compound 1 as obtained by the method disclosed in Example 5.
• Figure 5 shows the XRPD patterns of form VI of compound 1 as obtained by the method disclosed in Example 6.
• Figure 6 shows the XRPD patterns of form VII of compound 1 as obtained by the method disclosed in Example 7.
• Figure 7 shows the XRPD patterns of form VIII of compound 1 as obtained by the method disclosed in Example 8.
• Figure 8 shows the XRPD patterns of form IX of compound 1 as obtained by the method disclosed in Example 9.
• Figure 9 shows the XRPD patterns of form X of compound 1 as obtained by the method disclosed in Example 10.
• Figure 10 shows the XRPD patterns of form XI of compound 1 as obtained by the method disclosed in Example 11.
• Figure 11 shows the XRPD patterns of form XII of compound 1 as obtained by the method disclosed in Example 12.
• Figure 12 shows the XRPD patterns of form XIII of compound 1 as obtained by the method disclosed in Example 13.
• Figure 13 shows the XRPD patterns of form XIV of compound 1 as obtained by the method disclosed in Example 14.
• Figure 14 shows the XRPD patterns of form XV of compound 1 as obtained by the method disclosed in Example 15.
• Figure 15 shows the Raman spectrum of form XVI of compound 1 as obtained by the method disclosed in Example 16.
• Figure 16 shows the XRPD patterns of pattern 6 of compound 1 as obtained by the method disclosed in Example 17.
• Figure 17 shows the XRPD patterns of sulfuric acid salt of compound 1 as obtained by the method disclosed in Example 18.
• Figure 18 shows the XRPD patterns of hydrobromic acid salt of compound 1 as obtained by the method disclosed in Example 19.
• Figure 19 shows the XRPD patterns of hydrochloric acid salt of compound 1 as obtained by the method disclosed in Example 20.
• Figure 20 shows the XRPD patterns of form XVII of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 21 shows the XRPD patterns of form XVIII of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 22 shows the XRPD patterns of form XIX of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 23 shows the XRPD patterns of form XX of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 24 shows the XRPD patterns of form XXI of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 25 shows the XRPD patterns of form XXII of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 26 shows the XRPD patterns of form XXIII of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 27 shows the XRPD patterns of form XXIV of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 28 shows the XRPD patterns of form XXV of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• Figure 29 shows the XRPD patterns of form XXVI of compound 1 as obtained by the method disclosed in Examples 21 and 22.
• compound 1 as used herein means Propane- 1 -sulfonic acid ⁇ 3-[5-(4- chloro-phenyl)-lH-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl ⁇ -amide, which is sometimes also designated as PLX-4032.
• amorphous forms denotes a material that lacks long range order and as such does not show sharp X-ray peaks.
• amorphous form refers to the amorphous form of Propane- 1 -sulfonic acid ⁇ 3-[5-(4-chloro-phenyl)-lH-pyrrolo[2,3- b]pyridine-3-carbonyl]-2,4-difluoro-phenyl ⁇ -amide (compound 1) as such, provided said amorphous form does not form a one phase system, such as for example a solid dispersion or microprecipitated bulk powder (MBP) together with any type of supporting material such as polymers or the like.
• MBP microprecipitated bulk powder
• amorphous halo means a broad diffraction maximum in the X-ray powder diffraction pattern of an amorphous substance, i.e. the amorphous form of compound 1.
• the FWHM (full width at half maximum) of an amorphous halo is usually bigger than two degrees in 2-theta.
• the "Form ⁇ " of compound 1 as referred to herein means the thermodynamically stable form of Propane- 1 -sulfonic acid ⁇ 3-[5-(4-chloro-phenyl)-lH-pyrrolo[2,3-b]pyridine-3- carbonyl]-2,4-difluoro-phenyl ⁇ -amide.
• molecularly dispersed refers to the random distribution of compound 1 within a polymer. More particularly, a compound (for example, compound 1) may be dispersed within a matrix formed by the polymer in its solid state such that the compound 1 and the matrix form a one phase system (solid dispersion) and compound 1 is immobilized in its amorphous form.
• solid dispersion is a micro- precipitated bulk powder (MBP).
• MBP micro- precipitated bulk powder
• flash cooling means cooling with liquid nitrogen.
• polymorph as used herein means one of the different crystal structures in which a compound can crystallize. Polymorphs are best characterized by their space group and unit-cell parameters. This term is reserved for materials with the same elemental analysis.
• solvate as used herein means a crystal form that contains either stoichiometric or nonstoichiometric amounts of solvent.
• substantially amorphous material embraces material which has no more than about 10% crystallinity; and "amorphous” material embraces material which has no more than about 2% crystallinity. In some embodiments, the "amorphous" material means material having no more than 1%, 0.5% or 0.1 % crystallinity.
• Ambient temperature means any temperature in the range of 18 to 28 °C, preferably 20 to 24 °C.
• composition refers to a pharmaceutical preparation suitable for
• composition may include at least one additional pharmaceutically acceptable component to provide an improved formulation of the compound, such as a suitable carrier, additive or excipient.
• pharmaceutically acceptable indicates that the indicated material does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. For example, it is commonly required that such a material be essentially sterile, e.g., for injectibles.
• a therapeutically effective amount indicates that the materials or amount of material is effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or medical condition, and/or to prolong the survival of the subject being treated.
• a “therapeutically-effective amount” of Compound I refers to such dosages and/or administration for such periods of time necessary to inhibit human b-Raf containing the V600E mutation.
• the human b-Raf includes V600A, V600M, V600R, V600K or V600G mutations.
• a therapeutically effective amount may be one in which the overall therapeutically-beneficial effects outweigh the toxic or undesirable side effects.
• a therapeutically-effective amount of Compound I may vary according to disease state, age and weight of the subject being treated. Thus, dosage regimens are typically adjusted to the individual requirements in each particular case and are within the skill in the art. In certain embodiments, an appropriate daily dose for
• administration of Compound 1 to an adult human may be from about 100 mg to about 3200 mg; or from about 250 mg to about 2000 mg, although the upper limit may be exceeded when indicated.
• a daily dosage of Compound 1 can be administered as a single dose, in divided doses, or, for parenteral administration, it may be given as subcutaneous injection.
• Compound 1 and a polymer may be dissolved in a common solvent having a low boiling point, e.g., ethanol, methanol, acetone, etc.
• a common solvent having a low boiling point e.g., ethanol, methanol, acetone, etc.
• the solvent is evaporated by flash evaporation at the temperature close to boiling point or under a high vacuum (low vapor pressure), leaving the Compound 1 precipitated in a matrix formed by the polymer.
• Compound 1 is in a mesylate or tosylate salt form, and thus preferably has improved solubility.
• methacrylic acid copolymers as used herein in the spray dry dispersion process includes, but are not limited to, methacrylic acid copolymers, methacrylic acid - methacrylate copolymers, methacrylic acid - ethyl acrylate copolymers, ammonio
• a "methacrylic acid copolymer” may be EUDRAGIT® L 100 and
• EUDRAGIT® L 12,5 also referred to as, or conforms with: "Methacrylic Acid Copolymer, Type ⁇ ;” “Methacrylic Acid - Methyl Methacrylate Copolymer (1 : 1);” “Methacrylic Acid Copolymer L;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® S 100 and EUDRAGIT® S 12,5 (also referred to as, or conforms with: "Methacrylic Acid Copolymer, Type ⁇ ;"
• EUDRAGIT ® L 30 D-55 also referred to as, or conforms with: "Methacrylic Acid
• EUDRAGIT ® FS 30 D also referred to as DMF 13941 or DMF 2006-176
• EUDRAGIT ® RL 100 also referred to as, or conforms with: "Ammonio Methacrylate Copolymer, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type A);” "Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242” or “PR-MF 6918"
• EUDRAGIT ® RL PO also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242”
• EUDRAGIT ® RL 12,5 also referred to as, or conforms with "Ammonio Methacrylate Copolymer, Type ⁇ ;” "Ammonio Methacrylate Copolymer (Type A
• EUDRAGIT ® RL PO also referred to as, or conforms with: "Ammonio Methacrylate Copolymer, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” or “DMF 1242”); EUDRAGIT ® RL 12,5 (also referred to as, or conforms with: polymer conforms to "Ammonio Methacrylate Copolymer, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type A);” “DMF 1242” or “PR-MF 6918");
• EUDRAGIT ® RL 30 D also referred to as, or conforms with: “Ammonio Methacrylate Copolymer Dispersion, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type A);” or “DMF 1242”
• EUDRAGIT ® RS 100 also referred to as, or conforms with: "Ammonio
• EUDRAGIT ® RS PO also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type ⁇ ;” “Ammonio Methacrylate Copolymer (Type B);” “Aminoalkyl Methacrylate Copolymer RS;” or “DMF 1242”
• EUDRAGIT ® RS 12,5 also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type ⁇ ;” NF polymer conforms to "Ammonio Methacrylate Copolymer (Type B);” “DMF 1242” or “PR-MF 6918”
• EUDRAGIT ® RS 30 D also referred to as, or conforms with: "Ammonio Methacrylate Copolymer (Type B);” “DMF 1242” or “PR-MF 6918”
• EUDRAGIT ® RS 30 D also referred to as, or conforms with: "Ammonio Methacrylate Copolymer (Type B
• EUDRAGIT ® E PO also referred to as, or conforms with: “Basic Butylated Methacrylate Copolymer;” “Aminoalkyl Methacrylate Copolymer ⁇ ;” “Amino Methacrylate Copolymer;” “DMF 1242”
• EUDRAGIT ® E 12,5 also referred to as, or conforms with: “Amino Methacrylate Copolymer;” “Basic Butylated Methacrylate Copolymer;” “DMF 1242” or “PR-MF 6918”
• EUDRAGIT ® NE 30 D also referred to as, or conforms with: “Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion;" "Pol
• PLASTOID ® B also referred to as, or conforms with: "DMF 12102"
• API active pharmaceutical ingredient
• DSC Differential Scanning Calorimetry.
• DVD Dynamic Vapor Sorption.
• IR Infra Red spectroscopy.
• XRPD Raman spectroscopy.
• TGA ThermoGravimetric Analysis. Characterization Methods
• calorimeter DSC820, DSC821 or DSC 1 with a FRS05 sensor was used as reference substances and calibrations were carried out using Indium, Benzoic acid, Biphenyl and Zinc as reference substances.
• TGA analysis was performed on a Mettler-ToledoTM thermogravimetric analyzer (TGA850 or TGA851). System suitability tests were performed with Hydranal as reference substance and calibrations using Aluminum and Indium as reference substances.
• thermogravimetric analyses approx. 5 10 mg of sample were placed in aluminum pans, accurately weighed and hermetically closed with perforation lids. Prior to measurement, the lids were automatically pierced resulting in approx. 1.5 mm pin holes. The samples were then heated under a flow of nitrogen of about 50 mL/min using a heating rate of 5 K min.
• DVS isotherms were collected on a DVS-1 (SMS Surface Measurements Systems) moisture balance system.
• the sorption/desorption isotherms were measured stepwise in a range of 0% RH to 90% RH at 25 °C.
• a weight change of ⁇ 0.002 mg/min was chosen as criterion to switch to the next level of relative humidity (with a maximum equilibration time of six hours, if the weight criterion was not met).
• the data were corrected for the initial moisture content of the samples; that is, the weight after drying the sample at 0% relative humidity was taken as the zero point.
• IR spectra were recorded as film of a Nujol suspension of approximately 5 mg of sample and few Nujol between two sodium chloride plates, with an FTIR spectrometer in transmittance.
• the Spectrometer is a NicoletTM 20SXB or equivalent (resolution 2 cm-1, 32 or more coadded scans, MCT detector).
• Raman spectra were recorded in the range of 150-1800 cm “1 at excitation of 785 nm with an ARAMIS (HoribaJobinYvon) Raman microscope equipped with a Peltier cooled CCD detector, and a 1200 1/mm grating.
• ARAMIS HoribaJobinYvon
• X-ray powder diffraction patterns were recorded at ambient conditions in transmission geometry with a STOE STADIP diffractometer (Cu Ka radiation, primary monochromator, position sensitive detector, angular range 3 ° to 42 ° 2Theta, approximately 60 minutes total measurement time). Approximately 25 mg of sample were prepared and analyzed without further processing (e.g. grinding or sieving) of the substance.
• X-ray diffraction patterns were measured on a Scintag XI powder X-ray diffractometer equipped with a sealed copper Kal radiation source. The samples were scanned from 2° to 36° 2 ⁇ at a rate of 1° per minute with incident beam slit widths of 2 and 4 mm and diffracted beam slit widths of 0.3 and 0.2 mm.
• the amorphous form includes less than about 15%, preferably less than about 10%>, preferably less than about 5%, preferably less than about 1%, even more preferably less than 0.1% by weight of impurities, including other polymorph forms of compound 1.
• at least about 30-99% by weight of the total of compound 1 in the composition is present as the amorphous form.
• at least about 70%>, at least about 80%>, at least about 90%>, at least about 99% or at least about 99.9% by weight of the total of compound 1 in the composition is present as the amorphous form.
• compositions consisting essentially of compound 1 wherein at least about 97-99% by weight of the compound 1 is present in the composition as an amorphous form, a polymorph form, a solvate form as described herein or combinations thereof.
• the polymorph, solvate or amorphous form of compound I according to the present invention can also be present in mixtures.
• amorphous form XVII can be present in mixtures with one or more other amorphous forms selected from XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV or XXVI.
• Solvate form III can be present in mixtures with one or more solvate forms selected from IV, V, VI, VII, IX, X, XI, XII, XIII, XIV or XV.
• Polymorph form VIII can be present in a mixture with polymorph form XVI.
• Suitable solvents for preparation of spray dry dispersion amorphous forms of compound 1 include, but are not limited to acetone, water, alcohols, mixtures thereof, and the like.
• the alcohols include, but are not limited to, ethanol, methanol, isopropanol and mixtures thereof.
• the solid forms of compound 1 as disclosed herein can be used in a wide variety of preparations for administration of drugs, and in particular for oral dosage forms.
• Exemplary dosage forms include powders or granules that can be taken orally either dry or reconstituted by addition of water to form a paste, slurry, suspension or solution; tablets, capsules, or pills.
• Various additives can be mixed, ground or granulated with the solid dispersion as described herein to form a material suitable for the above dosage forms.
• Potentially beneficial additives may fall generally into the following classes: other matrix materials or diluents, surface active agents, drug complexing agents or solubilizers, fillers, disintegrants, binders and lubricants.
• pH modifiers e.g., acids, bases, or buffers
• matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch.
• surface active agents include sodium lauryl sulfate and polysorbate 80.
• Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins.
• Examples of disintegrants include sodium starch gycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, and croscarmellose sodium.
• Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth.
• Examples of lubricants include magnesium stearate and calcium stearate.
• pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids. At least one function of inclusion of such pH modifiers is to control the dissolution rate of the drug, matrix polymer, or both, thereby controlling the local drug concentration during dissolution.
• acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like
• bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like
• buffers generally comprising mixtures of acids and the salts of said acids
• a further embodiment includes a pharmaceutical preparation containing the solid dispersion as obtained by a method as described herein.
• the present invention provides a method for preparing a substantially amorphous form of compound (1), the amorphous form is selected from form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV or XXVI or combinations thereof.
• the method includes preparing a spray dry dispersion solution of compound (1) and drying the dispersion solution of compound (1) under conditions sufficient to obtain the amorphous form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV or XXVI or combinations thereof.
• the spray dry dispersion solution is dried under vacuum.
• a spray dry dispersion solution is prepared by dispersing a solution of compound (1) into a polymer solution under conditions sufficient to obtain the spray dry dispersion solution.
• Any solvents or a mixture of solvents that are suitable to dissolve compound (1) can be used.
• Exemplary solvents for dissolving compound (1) include , but are not limited to, tetrahydrofuran (THF), acetone, acetonitrile, benzene, ethanol, toluene, ether, ethyl acetate, dimethylformamide (DMF), dimethyl sulfoxide (DMSO) or a mixture of any two or more thereof.
• an acid such as hydrochloric acid, sulfuric acid or nitric acid is added into an organic solvent system in a ratio sufficient to assist the dissolution of compound (1).
• the polymer solution can be prepared by dissolving a polymer in an organic solvent or a mixture of solvents with a suitable ratio. In certain instances, the polymer is dissolved in a solvent or a mixture of solvents at a temperature ranging from 20 - 100 °C, 30-50 °C or 40-100 °C. Any polymers as described herein can be used for the preparation of the polymer solution.
• Exemplary solvents for preparing the polymer solution include, but are not limited to THF, acetone, acetonitrile, benzene, ethanol, toluene, ether, ethyl acetate, DMF, DMSO, H 2 0 or a mixture threof.
• the invention provides a method for treating a disease or condition in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a composition comprising at least one solid form of compound I selected from the group consisting of:
• a substantially amorphous form of compound 1 selected from form XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI or combinations thereof, wherein compound 1 is molecularly dispersed;
• the disease or condition for which the above-described method is employed is melanoma, thyroid cancer or colon cancer.
• the invention provides a method for treating a disease or condition in a mammal in need thereof, said method comprising administering to said mammal an effective amount of a composition comprising at least one solid form of compound I as described herein.
• the disease or condition for which the above-described method is employed is melanoma, thyroid cancer or colon cancer.
• Amorphous material can be generally obtained by flash cooling of a melt and spray drying. Other processes such as for example lyophilization may also be used. a) Preparation of amorphous material by spray drying
• the amorphous form can be characterized by the lack of sharp X-ray diffraction peaks in its XRPD pattern, as well as a glass transition temperature as obtainable via DSC measurement in the range of about 100 °C to 110 °C. The exact glass transition temperature is largely dependent on the water/solvent content.
• Figure 1 shows XRPD patterns of the amorphous form of compound 1 as obtainable by the method disclosed in this example.
• Polymorphic form I can generally be obtained by drying of the hemi-acetone solvate (Form IX) at >70 °C.
• Form IX hemi-acetone solvate
• Form III can be characterized by XRPD patterns obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 9.5, 10.0, 13.0,
• Form IV is a THF 0.75-solvate and can be generally obtained by processes
• Form IV can be characterized by its XRPD patterns obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 5.5, 7.4, 11.0, 13.4,
• Figure 3 shows the XRPD pattern of a typical lot of form IV of compound 1.
• Form V is a dioxane mono-solvate and can be obtained by processes comprising compound 1 and dioxane as solvent. a) Preparation of form V by equilibration in dioxane
• Form V can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 12.7, 13.1, 14.3, 16.3, 19.0, 20.1, 22.4, 25.1, 27.1, 28.9.
• Figure 4 shows the XRPD pattern of a typical lot of form V of compound 1.
• Form VI is a DMF mono-solvate and can be obtained by procedures comprising compound 1 and DMF as solvent. a) Preparation of form VI by equilibration in DMF
• Form VI can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 7.8, 10.3, 11.4, 11.8, 15.1, 15.6, 16.1, 16.6, 18.6, 18.9, 19.2, 20.4, 21.0, 21.6, 22.8, 24.6, 25.1, 25.8, 26.1, 27.4, 28.8.
• Figure 5 shows the XRPD pattern of a typical lot of form VI of compound 1.
• Form VII is a THF hemi-solvate and can be obtained by processes comprising compound 1 and THF as solvent. a) Preparation of form VII by equilibration in THF
• Form VII can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 7.6, 9.4, 9.9, 13.1, 15.9, 16.2, 17.0, 18.1, 18.8, 19.9, 20.5, 20.7, 21.4, 21.8, 24.3, 24.9, 25.3.
• Figure 6 shows the XRPD pattern of a typical lot of form VII of compound 1.
• Form VIII can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 5.0, 11.3, 11.6, 12.0, 13.8, 16.2, 16.7, 19.0, 20.1, 20.8, 22.5, 27.1.
• Figure 7 shows the XRPD pattern of a typical lot of form VIII of compound 1.
• Form IX is an acetone hemi-solvate and can be obtained by processes comprising compound 1 and acetone as solvent. a) Preparation of form IX by equilibration in acetone
• Form IX can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 9.5, 9.9, 13.0, 15.9, 16.4, 17.0, 17.9, 18.7, 19.9, 20.7, 21.7, 24.8, 25.1.
• Figure 8 shows the XRPD pattern of a typical lot of form IX of compound 1.
• Form X is a pyridine mono-solvate and can be generally obtained by processes comprising compound 1 and pyridine as solvent. a) Preparation of form X by equilibration in pyridine
• Form X can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately: 7.4, 9.2, 10.8, 13.6, 14.9, 19.0, 20.2, 21.4, 22.4, 23.7, 25.5, 27.0, 29.
• Figure 9 shows the XRPD pattern of a typical lot of form X of compound 1.
• Form XI is a 2-methylpyridine mono-solvate and can be generally obtained by processes comprising compound 1 and 2-methylpyridine as solvent. a) Preparation of form XI by evaporative crystallization from 2- methylpyridine
• Form XI can be characterized by its XRPD pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 8.0, 12.1, 12.6, 13.4, 13.9, 14.8, 16.2, 17.6, 18.5, 19.2, 20.1, 21.0, 21.4, 21.7, 23.5, 25.3, 25.5, 26.6, 27.0, 30.8.
• Figure 10 shows the XRPD pattern of a typical lot of form XI of compound 1.
• Form XII is a diisopropylamine mono-solvate and can generally be obtained by processes comprising compound 1 and diisopropylamine as solvent. a) Preparation of form XII by evaporative crystallization from 2- methylpyridine
• Form XII can be characterized by an X-ray powder diffraction pattern obtained with Cu K a radiation having characteristic peaks expressed in degrees 2Theta at approximately: 7.5, 9.9, 12.1, 13.6, 16.2, 16.7, 17.1, 17.5, 18.3, 18.5, 20.1, 21.7, 22.4, 23.4, 24.3, 25.6, 26.9, 31.6.
• Figure 11 shows the XRPD pattern of a typical lot of form XII of compound 1.
• Form XIII is a morpholine mono-solvate and can generally be obtained by processes comprising compound 1 and morpholine as solvent. a) Preparation of from XIII by incubation with morpholine vapor
• From XIII can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 5.1, 5.8, 6.9, 15.3, 16.2, 17.4, 18.4, 18.9, 19.5, 20.4, 21.1, 21.5, 22.2, 22.6, 25.2, 25.7.
• Figure 12 shows the XRPD pattern of a typical lot of form XIII of compound 1.
• Form XIV is a DMSO mono-solvate and can be generally obtained by processes comprising compound 1 and DMSO as solvent. a) Preparation of form XIV by evaporative crystallization from DMSO
• Form XIV can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 5.2, 10.2, 12.9, 13.9, 17.1, 17.6, 18.7, 19.8, 20.1, 20.5, 21.0, 21.7, 22.8, 24.1, 25.1, 25.5, 27.1, 27.4.
• Figure 13 shows the XRPD pattern of a typical lot of form XIV of compound 1.
• Form XV is a DMSO mono-solvate and can generally be obtained by processes comprising compound 1 in DMSO as solvent. a) Preparation of form XV by incubation with DMSO vapor
• Form XV can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 12.6, 13.8, 14.6, 16.2, 16.6, 17.8, 18.3, 20.4, 20.7, 21.4, 22.4, 23.2, 24.2, 24.5, 25.5, 26.9, 27.8, 28.7.
• Figure 14 shows the XRPD pattern of form XV of compound 1.
• Polymorphic form XVI can be obtained by heating amorphous melt films on glass slides. Form XVI could not be crystallized pure, but with form VIII. a) Preparation of form XVI
• Form XVI can be characterized by a Raman spectrum as shown in Figure 15.
• Pattern 6 can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 7.0, 8.4, 8.9, 13.0, 13.8, 17.7, 18.8, 20.7, 25.8, 29.7.
• Figure 16 shows the XRPD pattern of Pattern 6 of compound 1.
• the sulfuric acid salt can be obtained by processes, comprising compound 1 and sulfuric acid. a) Preparation of the sulfuric acid salt in tetrahydrofuran
• the sulfuric acid salt can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 4.7, 6.7, 10.6, 13.3, 14.5, 15.7, 16.4, 18.3, 18.6, 18.9, 19.5, 20.1, 20.9, 21.2, 23.2, 23.7, 24.0, 26.9, 30.0.
• Figure 17 shows the XRPD pattern of a typical lot of sulfuric acid salt of compound 1.
• the sulfuric acid salt of compound 1 can be further characterized by a melting point with onset temperature (DSC) of about 221 °C to 228 °C.
• the hydrobromic acid salt can be obtained by processes comprising compound 1 and hydrogen bromide. a) Preparation of the hydrobromic acid salt in tetrahydrofuran
• the bromide salt can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at approximately 5.7, 6.8, 1 1.4, 13.6, 18.1, 19.8, 20.2, 21.4, 21.8, 24.6, 26.1, 27.3, 29.2.
• Figure 18 shows a XRPD pattern of a typical lot of bromide salt of compound l .
• This salt can be further characterized by a melting point with onset temperature (DSC) in the range of about 240 °C to 246 °C. Melting occurs under decomposition and can vary substantially.
• the hydrochloric acid salt can be obtained by processes comprising compound 1 and hydrogen chloride. a) Preparation of the hydrochloric acid salt in tetrahydrofuran
• the chloride salt can be characterized by an X-ray powder diffraction pattern obtained with Cu Ka radiation having characteristic peaks expressed in degrees 2Theta at
• Figure 19 shows the XRPD pattern of a typical lot of hydrochloric acid salt of compound 1.
• HPMCAS hydroxypropyl methyl cellulose acetate succinate
• L100-55 ethylacrylate
• PVPVA vinylpyrrolidone-vinyl acetate
• Each formula was spray dried using a target inlet temperature of 100-105 °C, an outlet temperature of 55 °C, and an atomizing gas pressure of 0.5 bar.
• the feed material was atomized using a 0.5 mm two-fluid Schlick nozzle for all runs. Collection of the product is at the cyclone.
• Spray dried dispersions were vacuum oven dried overnight for 65 hours at 37 °C under a reduced pressure between -25 to -30 in Hg (Stage 1). These samples were further vacuum oven dried for an additional 65 hours at 45 °C under a reduced pressure between -25 to -30 in Hg (Stage 2). Spray dried dispersions were vacuum oven dried for 65 hours at 45 °C under a reduced pressure between -25 to -30 in Hg. Residual solvent are below 5000 PPM.
• Spray dry dispersion solutions for amorphous forms XVII, XVIII, XIX, XX, XXI, XXIII, XXIV, XXV or XXVI were prepared according to the procedure set forth in Example 21.
• Spray dry dispersion formulas of amorphous forms XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV or XXVI were prepared according to the procedure set forth in Example 22.
• Table 1 illustrates the spray dry dispersion of formulations of amorphous forms XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV and XXVI.
• Table 1 illustrates the spray dry dispersion of formulations of amorphous forms XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV and XXVI.
• Solid form XVII was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak with minor sharp peaks expressed in degrees 2Theta. The locations of the minor sharp peaks are shown in the table below.
• Figure 20 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XVII.
• Solid form XVIII was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation. The X-ray powder diffraction pattern exhibits two broad halo peaks expressed in degrees 2Theta as shown in Figure 21. c) Characterization of solid form XIX
• Solid form XIX was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak with minor sharp peaks expressed in degrees 2Theta.
• Figure 22 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XIX. d) Characterization of solid form XX
• Solid form XX was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak with minor sharp peaks expressed in degrees 2Theta.
• Figure 23 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XX.
• Solid form XXI was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak with minor sharp peaks expressed in degrees 2Theta.
• Figure 24 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXI. fi Characterization of solid form XXII
• Solid form XXII was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak expressed in degrees 2Theta.
• Figure 25 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXII.
• Solid form XXIII was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak expressed in degrees 2Theta.
• Figure 26 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXIII.
• Solid form XXIV was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak with minor sharp peaks expressed in degrees 2Theta.
• Figure 27 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXIV. i) Characterization of solid form XXV
• Solid form XXV was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak expressed in degrees 2Theta.
• Figure 28 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXV.
• Solid form XXVI was characterized by X-ray powder diffraction analysis obtained with Cu Ka radiation.
• the X-ray powder diffraction pattern consists of a broad halo peak expressed in degrees 2Theta.
• Figure 29 shows a XRPD pattern of a typical lot of a substantially amorphous solid state form XXVI..

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicinal Preparation (AREA)
• Pyrrole Compounds (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Publications (1)

Family

ID=47217568

Family Applications (1)

Country Status (17)

Cited By (14)

Families Citing this family (55)

Citations (2)

Family Cites Families (246)

• 2012
  • 2012-02-17 TW TW101105224A patent/TWI558702B/zh active
  • 2012-02-17 AR ARP120100546A patent/AR085279A1/es unknown
  • 2012-02-21 CN CN2012800097909A patent/CN103442767A/zh active Pending
  • 2012-02-21 KR KR1020137024311A patent/KR20140011340A/ko not_active Ceased
  • 2012-02-21 CA CA2827708A patent/CA2827708A1/en not_active Abandoned
  • 2012-02-21 WO PCT/US2012/025965 patent/WO2012161776A1/en not_active Ceased
  • 2012-02-21 EP EP17170715.1A patent/EP3281675A1/en not_active Withdrawn
  • 2012-02-21 US US13/817,124 patent/US8865735B2/en active Active
  • 2012-02-21 AU AU2012259422A patent/AU2012259422B2/en active Active
  • 2012-02-21 SG SG2013061007A patent/SG192722A1/en unknown
  • 2012-02-21 BR BR112013021103-2A patent/BR112013021103A2/pt not_active Application Discontinuation
  • 2012-02-21 CN CN201610829679.4A patent/CN106632314A/zh active Pending
  • 2012-02-21 MY MYPI2013701465A patent/MY163083A/en unknown
  • 2012-02-21 EP EP12789648.8A patent/EP2678075A4/en not_active Withdrawn
  • 2012-02-21 RU RU2013143010/04A patent/RU2013143010A/ru unknown
  • 2012-02-21 JP JP2013554678A patent/JP2014505740A/ja active Pending
  • 2012-02-21 MX MX2013009558A patent/MX2013009558A/es unknown
• 2013
  • 2013-08-08 IL IL227862A patent/IL227862A0/en unknown
  • 2013-08-19 ZA ZA2013/06237A patent/ZA201306237B/en unknown
• 2016
  • 2016-02-26 JP JP2016036273A patent/JP2016153404A/ja active Pending

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events